Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Nov 28, 2022 5:39pm
181 Views
Post# 35135112

RE:Decreasing volume/turnover?

RE:Decreasing volume/turnover?
EbbFlow88 wrote: I've noticed recently that the daily volume has decreased in the last 6 months compared to the past. Could be just a coincidence, but maybe it's a sign that the shareholder turnover is slowing. With insiders owning more than 20% and if Armoyan owns 10%, and the company buying back 10% of the float per year recently, the weak hands should be running out. 

Should bode well if/when the market begins to notice the postive growth in Knight.




Ya - Armoyan is an early adoptor.
Others will eventually follow.

I think that's still one or two big drug mores away - then you have to see the revenue effects - before others say ... water is fine - you can jump in now.



<< Previous
Bullboard Posts
Next >>